ASLAN Pharmaceuticals to Present at the Annual Needham Virtual Healthcare Conference 2022
ASLAN Pharmaceuticals (Nasdaq:ASLN) announced that CEO Dr. Carl Firth will present at the 21st Annual Needham Virtual Healthcare Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
ASLAN Pharmaceuticals (Nasdaq:ASLN) announced that CEO Dr. Carl Firth will present at the 21st Annual Needham Virtual Healthcare Conference. This event will take place from April 11 to 14, 2022, with Dr. Firth's presentation scheduled for April 14, 2022, from 10:15 to 10:55 AM ET. The presentation will be available for live listening and replay through the company's investor relations website. ASLAN is focused on developing innovative immunology treatments, including eblasakimab for atopic dermatitis and farudodstat for autoimmune diseases.
Details
News Market Reaction – ASLN
The recorded move for ASLN in the trading session of this news was +1.40%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MENLO PARK, Calif. and SINGAPORE, April 06, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that Dr Carl Firth, CEO, will present at the 21st Annual Needham Virtual Healthcare Conference. The conference will be held virtually from April 11 to 14, 2022.
Presentation details
Date: Thursday, April 14, 2022
Time: 10:15 - 10:55am ET
Format: Company presentation
Track: 2
Click here to listen-in live or via replay. This link will also be posted in the News & Events section of ASLAN Pharmaceutical’s Investor Relations website at https://ir.aslanpharma.com/.
Ends
Media and IR contacts
| Emma Thompson Spurwing Communications Tel: +65 6206 7350 Email: ASLAN@spurwingcomms.com | Ashley R. Robinson LifeSci Advisors, LLC Tel: +1 (617) 430-7577 Email: arr@lifesciadvisors.com |
About ASLAN Pharmaceuticals
ASLAN Pharmaceuticals (Nasdaq:ASLN) is a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients. ASLAN is currently evaluating eblasakimab, a potential first-in-class antibody targeting the IL-13 receptor, in atopic dermatitis, and farudodstat (also known as ASLAN003), a potent oral inhibitor of the enzyme, DHODH, in autoimmune disease. ASLAN has a team in Menlo Park, California, and in Singapore. For additional information please visit www.aslanpharma.com or follow ASLAN on LinkedIn.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.